ICH guideline E14 - the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (R3) – questions and answers

We have adopted this International Scientific Guideline - ICH E14; EMA/CHMP/ICH/310133/2008

Last updated

29 August 2024

About this guideline

For information: 25 January 2016

Categories: ICH | Efficacy

Clinical efficacy and safety | Cardiovascular system | Arrythmias

TGA Annotations: Nil

Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

Topics